Fitxers

708514.pdf (467.97 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-02-26

Llicència de publicació

cc-by (c) Solanich, Xavier et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/176144

Clinical significance of indeterminate QuantiFERON-TB Gold Plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm10050918

Resum

Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March-April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002-1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397-14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; p = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated.

Matèries

COVID-19, Mortalitat

Matèries (anglès)

COVID-19, Mortality

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SOLANICH, Xavier, et al. Clinical significance of indeterminate QuantiFERON-TB Gold Plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome. Journal of Clinical Medicine. 2021. Vol. 10, num. 5, pags. 918. ISSN 2077-0383. [consulted: 24 of May of 2026]. Available at: https://hdl.handle.net/2445/176144

Exportar metadades

JSON - METS

Compartir registre